Thursday, August 11, 2022

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

At the time of approval, ide-cell was the first FDA cell-based gene therapy for multiple myeloma. KarMMa-3 (NCT03651128) is a randomized, global, ...
https://www.google.com/url?rct=j&sa=t&url=https://www.ajmc.com/view/topline-karmma-3-results-for-ide-cel-in-multiple-myleoma-show-significant-improvement-in-pfs&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw0noQrppzP8SLpXfhvhlVz4

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...